^
    Back
    Association details:
    Biomarker:HER-2 overexpression
    Cancer:Esophageal Adenocarcinoma
    Drug:Herceptin (trastuzumab) (HER2 inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: A2 - Guideline
    New
    Source:
    NCCN
    Excerpt:
    Esophageal and Esophagogastric Junction cancer...Trastuzumab should be added to first-line chemotherapy for HER2 overexpressing metastatic adenocarcinoma...Esophageal and Esophagogastric Junction Cancers: HER2 overexpression positive adenocarcinoma...Fluoropyrimidine (fluorouracil or capecitabine) and oxaliplatin and trastuzumab…Fluoropyrimidine (fluorouracil or capecitabine) and cisplatin and trastuzumab…Esophageal and Esophagogastric Junction Cancers: Other Recommended Regimens (trastuzumab should be added to first-line chemotherapy for HER2 overexpression positive adenocarcinoma)...Fluorouracil, and irinotecan…Paclitaxel with or without cisplatin or carboplatin…Docetaxel with or without cisplatin…Fluoropyrimidine (fluorouracil or capecitabine)…Docetaxel, cisplatin or oxaliplatin, and fluorouracil…Docetaxel, carboplatin, and fluorouracil (category 2B)…
    Secondary therapy:
    cisplatin; cisplatin + capecitabine; carboplatin + paclitaxel; docetaxel; 5-fluorouracil + oxaliplatin; carboplatin + docetaxel + 5-fluorouracil; cisplatin + paclitaxel; 5-fluorouracil; capecitabine + oxaliplatin; Chemotherapy; paclitaxel; 5-fluorouracil + irinotecan; capecitabine; cisplatin + 5-fluorouracil
    Evidence Level:
    Sensitive: B - Late Trials
    Source:
    Lancet Oncol
    Title:

    Trastuzumab with trimodality treatment for oesophageal adenocarcinoma with HER2 overexpression (NRG Oncology/RTOG 1010): a multicentre, randomised, phase 3 trial

    Published date:
    01/14/2022
    Excerpt:
    CONTRADICTING EVIDENCE: The addition of trastuzumab to neoadjuvant chemoradiotherapy for HER2-overexpressing oesophageal cancer was not effective.
    Secondary therapy:
    carboplatin + paclitaxel
    DOI:
    10.1016/S1470-2045(21)00718-X
    Trial ID:
    NCT01196390
    Evidence Level:
    Sensitive: B - Late Trials
    Source:
    ESMO-GI 2020
    Title:

    O-10 Trastuzumab with trimodality treatment for esophageal adenocarcinoma with HER2 overexpression: NRG Oncology/RTOG 1010

    Published date:
    07/08/2020
    Excerpt:
    CONTRADICTED EVIDENCE: The addition of trastuzumab to trimodality treatment did not improve DFS for patients with HER2 overexpressing esophageal adenocarcinoma.
    Secondary therapy:
    carboplatin + bisphosphonate bound paclitaxel
    DOI:
    https://doi.org/10.1016/j.annonc.2020.04.063
    Evidence Level:
    Sensitive: C1 - Off-label
      (Approved for Gastric Cancer)
    New
    Excerpt:
    Herceptin should only be used in patients with metastatic gastric cancer whose tumours have HER2 overexpression...
    Evidence Level:
    Sensitive: C3 – Early Trials
    New
    Source:
    Onco Targets Ther
    Title:

    Trastuzumab in the management of gastroesophageal cancer: patient selection and perspectives

    Excerpt:
    The combination of trastuzumab significantly improved objective RR, progression-free survival (PFS) and OS with the primary end point of median OS improved from 11.1 to 13.8 months. A preplanned exploratory analysis according to HER2 status suggested that OS was improved in patients with high expression of HER2. Patients with the strongest expression (IHC 3+) with concomitant FISH gene amplification received the greatest benefit, with an absolute improvement in OS of .5 months (12.3 compared to 17.9 months).
    Secondary therapy:
    cisplatin
    DOI:
    10.2147/OTT.S100643